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Abstract: Our understanding of the structure–function relationships of biomolecules and thereby
applying it to drug discovery programs are substantially dependent on the availability of the struc-
tural information of ligand–protein complexes. However, the correct interpretation of the electron
density of a small molecule bound to a crystal structure of a macromolecule is not trivial. Our
analysis involving quality assessment of ~0.28 million small molecule–protein binding site pairs
derived from crystal structures corresponding to ~66,000 PDB entries indicates that the majority
(65%) of the pairs might need little (54%) or no (11%) attention. Out of the remaining 35% of pairs
that need attention, 11% of the pairs (including structures with high/moderate resolution) pose
serious concerns. Unfortunately, most users of crystal structures lack the training to evaluate the
quality of a crystal structure against its experimental data and, in general, rely on the resolution as a
‘gold standard’ quality metric. Our work aims to sensitize the non-crystallographers that resolution,
which is a global quality metric, need not be an accurate indicator of local structural quality. In this
article, we demonstrate the use of several freely available tools that quantify local structural quality
and are easy to use from a non-crystallographer’s perspective. We further propose a few solutions
for consideration by the scientific community to promote quality research in structural biology and
applied areas.
Keywords: quality assessment; ligand–protein crystal structures; resolution; electron density map;
binding pose; PDB
1. Introduction
Macromolecular X-ray crystallography (MX) has advanced greatly since the report
of the first protein crystal structure of myoglobin (resolved at 6 Å) in 1958 [1]. Structure
determination of macromolecules using crystallography has become a routine practice
due to advancements in hardware and software. On the one hand, this advancement
has tremendously improved our understanding of biomolecular structure–function rela-
tionships. On the other hand, such technological advances have enabled many untrained
researchers to attempt MX. Other techniques such as nuclear magnetic resonance (NMR) [2]
and, more recently, cryo-electron microscopy (Cryo-EM) [3] also contribute immensely to
the biopharmaceutical research efforts. It is delightful to note that we are in an era that
is witnessing one of the most exciting impacts of the advancement of structure determi-
nation techniques. In just about a year, more than 1000 structures (as of March 2021) of
different proteins of SARS-CoV-2 (the causative agent of COVID-19) have been deposited
in the Protein Data Bank (PDB) [4], and the number is likely to increase in the future. In
accordance with the trend of the entire PDB [5], most of the SARS-CoV-2 protein structures
currently available in the PDB were also obtained using MX [6]. The vast structural data
openly available from the PDB provide an insight into the molecular mechanism of diseases,
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thereby accelerating drug discovery [7,8]. Reports show that structural data obtained from
the PDB also drive research efforts in various interdisciplinary areas beyond the boundaries
of classical structural biology [9].
High-quality crystal structures of ligand-bound macromolecules form a crucial starting
point in drug discovery pipelines. The quality of the input structures greatly influences
the outcomes of virtual screening experiments. However, what is referred to as a structure
is a model which is built into the electron density map. Over- or under-interpretation
of the density can lead to incorrect models built into the density. Mistakes can also
happen either due to the bias introduced during the structure determination process
or bias inherent in the crystallographer while interpreting the electron density. Often,
deciphering the correct ligand (for example, small organic molecules, ions, and water) in the
macromolecular binding site that fits the observed electron density is not a trivial task [10].
Hence, many expert crystallographers have expressed their concern over the quality of
protein–small molecule crystal structures deposited in the PDB and recommend users to
inspect the atomic co-ordinates against the electron density [11–16]. Examining a ligand’s
goodness of fit to the observed electron density can be challenging for non-crystallographer
users, who generally lack the training to critically evaluate the crystallographic data. This
advocates for the implementation of quality metrics that are easy to interpret from a
non-crystallographer’s perspective. The current PDB validation pipeline includes metrics
such as the real space correlation coefficient (RSCC) and the real space R-factor (RSR) that
indicate overall agreement between the ‘calculated’ and ‘observed’ electron density of a
ligand and protein residues [17]. These measures are helpful but have their limitations [18].
In 2014, the PDB validation pipeline was integrated into the wwPDB (Worldwide PDB)
OneDep deposition/biocuration/validation system for crystal structures. The OneDep
system allows structure depositors to view the validation results prior to and during the
deposition process. Pre-deposition validation reports help the depositors to make any
necessary corrections before their PDB entries are made publicly available. However,
comparative analysis of the PDB structures deposited before (2012–2013; ‘Legacy group’)
and after (2014–2015; ‘New group’) the deployment of the wwPDB OneDep system indicates
no marked improvement in the quality of the bound ligands [15]. The median and inter-
quartile range of RSCC and RSR values of ligands show little or no changes between the
Legacy and New groups.
Among the vast majority of the user community, the most widely used quality metric
is ‘resolution’ [19]. Studies in the past have highlighted that global quality indicators such
as resolution and Rfree need not always be a good choice of metrics to judge the local
quality (ligand and/or binding site residues) of a crystallographic model [11,15]. In the
current work, our analysis on ~0.28 million binding sites (obtained from ~66,000 PDB
entries) also echoes the fact that the quality of the local fit of a crystallographic model to
its electron density is independent of the resolution at which the structure is determined.
Our results show that more than half (38,693 out of 61,857; 62.5%) of the ligands identified
to have major concerns (‘Bad’ quality) are determined at a resolution of 2.5 Å or better.
These findings highlight the importance of assessing the quality of local regions of interest,
thereby aiming to prevent any possible over-interpretation of the reported co-ordinates.
Existing easy-to-use resources such as TWILIGHT [20], VHELIBS [21], EDIA [18], polder
OMIT maps [22], ToBvalid [23], and the PDBe website [24,25] can be of great help to guide
non-crystallographers in structure selection and local quality assessment. With the help
of multiple case studies in this article, we demonstrate how some of these tools could
be integrated into investigations. We believe our attempts would sensitize the users that
resolution should not be the sole criterion in choosing a crystal structure as input. Besides
the agreement of the reported model with experimental evidence, the ligand geometry and
the stereochemical compatibility of the ligand pose with the surrounding environment are
also important quality metrics that should be considered while evaluating a structure’s
quality [26]. However, detailed discussion of these parameters is beyond the scope of our
current study.
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To retain the scientific spirit of this work, we preferred not to reveal the identity (PDB
code, HET code, residue number, protein’s and ligand’s name) of the structures discussed
in this article. Revealing the identity of the structures might distract the readers, leading
to chances of humanizing the questionable structures with any researchers or their group.
‘To err is human’—given the complexities and challenges involved in determining protein–
small molecule crystal structures, error-free outcomes cannot always be expected, especially
from inexperienced crystallographers [27–29]. While experienced crystallographers can
appreciate the presence of low structural quality in local regions of a high-resolution
structure, non-crystallographer users are generally unaware of such problems. The main
focus of this report is to sensitize the non-crystallographer user community that there can
be local regions of unacceptable quality even in an atomic-resolution structure. Through
this article, we also intend to encourage the users to adopt quality check protocols as an
integral practice before starting with any structure-based investigations. We discuss several
strategies that one can implement to assess local structural quality. Unfortunately, our
policy of discussing the structures without revealing their identity prevented us from giving
due credit (in the form of citations) to the authors of the publications associated with the
respective structures. However, full details with disclosure of the structures’ identities and
literature references to the associated structures discussed in the case studies (Section 2.3)
were submitted to the journal for peer review only. The data presented in each table (main
and supplementary), description provided in the figure legends, and all other relevant
details required for verification of this work were provided to the reviewers and editors
with disclosure of the identities of the structures. We also submitted the quality assessment
reports of ~0.28 million pairs of protein–small molecule binding site and the corresponding
PDB codes, HET codes, residue numbers, and chain identities for peer review.
2. Results
2.1. General Analyses
We performed a quality assessment of ~0.28 million pairs (derived from crystal struc-
tures corresponding to 66,851 PDB entries) of small molecule ligands and respective protein
binding site residues using VHELIBS [21]. VHELIBS assigns a quality score to ligands
and each binding site residue based on parameters such as RSCC, B-factors, occupancy,
and a few others (for details, see Section 4.2). It then classifies the ligands/binding site
residues as ‘Good’ (score = 0), ‘Dubious’ (0 < score ≤ 2), or ‘Bad’ (score > 2) based on
the quality score. The VHELIBS assessment on our dataset shows that only 27% of the
ligands are highly reliable, belonging to the ‘Good’ (‘G’) category. A total of 22% of the
ligands are ‘Bad’ (‘B’) and need attention before using them for any practical applications,
such as drug discovery/design or generating benchmark datasets to evaluate docking
algorithms. A total of 51% of the remaining ligands are classified as ‘Dubious’ (‘D’) that are
not highly reliable. However, these ligands do not pose a severe quality-related concern.
A similar trend is observed in the quality of the binding site residues (Figure 1). In total,
only a small fraction (11%) of the entire dataset could qualify, according to the eligibility
criteria, for highly reliable ligand–protein binding site pairs (i.e., GG category). The inferior
quality of the ligand–protein binding site pairs (i.e., BB category) comprises 11% of the
whole dataset. The remaining 78% of the ligand–protein binding site pairs belong to one
of the following intermediate categories: GD/GB/DG/DD/DB/BG/BD. Our analysis
suggests that although the number of protein–ligand crystal structures deposited in the
PDB has increased steadily over the years, the quality trend has remained more or less
similar (Figure 2). For selected cases, the quality of fit of the ligands and residues was
visually inspected against the corresponding electron density maps, the details of which
are discussed later (Section 2.3). The complete list of the 66,851 PDB entries used for our
analyses is provided as a supplementary table (Table S1).
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2.2. Local Quality and Resolution
We studied the distribution of VHELIBS quality scores against the resolution of the cor-
responding structures to understand the influence of resolution on local (ligands/protein
binding sites) structural quality. This analysis revealed no clear trend between the quality of
the ligands/protein binding sites and the structure’s global resolution (Figure 3). However,
some apparently unexpected observations (especially from non-crystallographers’ per-
spective) were noted. Our analysis showed that 62.6% out of the 61,857 ligands (i.e., ~14%
of the 0.28 million ligands investigated) that belong to the ‘Bad’ category are bound to
crystal structures determined at 2.5 Å or better resolution. For most structure-based drug
design studies, a resolution of 2.5 Å or better is generally accepted as a reliable cut-off by
the scientific community and is often used as a primary filter to select structures from the
PDB [30–34]. The analysis further indicates that it is unlikely to obtain ‘Good’ ligands in the
structures with a resolution poorer than 4.5 Å. However, the ‘Bad’ ligands need not be re-
stricted to only poorer resolution and can even be found in crystal structures determined at
near-atomic resolution (better than 1.2 Å), as discussed later in case study-2 (Section 2.3.2).
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NTP values were calculated using the equation mentioned in Section 4.6. The number of protein–ligand binding site pairs
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ligand has achieved in our dataset (Figure 3). The binding site is also categorized as ‘Bad’ 
(quality score = 4) and VHELIBS identified multiple residues to be examined further. Visual 
inspection  revealed  that  the  ligand  is  hardly  supported  by  the  electron  density.  Several 
binding  site  residues  lack  adequate  electron  density  support  (Figure  4).  Some  of  these 
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Figure 3. Distribution of quality scores obtained from VHELIBS vs. resolution (Å) of the corresponding structure.
(A) ality score of ligands vs. res lution. (B) Quality score of protein binding sites vs. resolution. The green, yel-
low, and red circles represent ‘Good’ (score = 0), ‘Dubious’ (0 < score ≤ 2), and ‘Bad’ (score > 2) categories, resp ctively. The
vertical dashed lines in both the plots are drawn at 2.5 Å, which highlight some of the structures ith the worst local quality
scores (indicated by black arrows) that are solved at a resolution better than 2.5 Å. Each plot contains 276,377 data points.
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2.3. Case Studies
In this section, we highlight some examples of resolution-independent quality con-
cerns in ligand-bound protein crystal structures. We also demonstrate the applicability
of a few freely available computational resources that can help verify the quality of the
local structures. In all the subsequent sections, the proteins are denoted with the letter ‘P’
suffixed by numbers. A similar nomenclature strategy is also applied to the ligands (‘L’)
and the respective complexed structure (‘C’).
2.3.1. Case Study-1
This is an example of a complex, C1, comprising a protein, P1, bound to a ligand, L1.
The protein in question is an important drug target for the treatment of a form of cancer.
VHELIBS and Visual Inspection
In this complex, VHELIBS [21] categorized the ligand L1 as ‘Bad’ with a quality
score = 7 (for details on the methodology, see Section 4.2), which is the worst score that any
ligand has achieved in our dataset (Figure 3). The binding site is also categorized as ‘Bad’
(quality score = 4) and VHELIBS identified multiple residues to be examined further. Visual
inspection revealed that the ligand is hardly supported by the electron density. Several
binding site residues lack adequate electron density support (Figure 4). Some of these
residues are mentioned in the associated publication to be crucial for interactions with
the ligand L1. However, due to the inadequate support of the electron density around
the residues, the reported atomic co-ordinates need attention. The associated publication
reported four crystal structures including C1. These four crystal structures (C1, C2, C3, and
C4) comprise an identical protein, P1—each bound to two ligands at two different binding
sites (S1 and S2). The structures C1, C2, C3, and C4 are resolved at 2.3 Å, 2.3 Å, 2.4 Å,
and 2.5 Å, respectively. Site S1 of P1 is occupied by four different ligands (L1, L2, L3, and
L4) in each of the four crystal structures. These are the novel inhibitors identified by the
authors that are expected to bind to S1, aiding in drug development against the resistant
form of the cancer of interest. At S2, P1 is bound to the endogenous ligand (L’) in all four
structures. Most of the currently available drugs target S2, but development of resistance is
quite common. Therefore, identifying inhibitors that target a site other than S2 will aid in





















which  the  respective  ligand  is bound  at  site S1. The  ligand L’  at  S2  is  categorized  as 
‘Dubious’ by VHELIBS in all four complexes, indicating no major quality concerns. Visual 
inspection confirmed  that L’  is adequately supported by  the electron density  in all  the 
complexes  (Figure  5),  but  the  ligands  bound  at  S1  in  all  four  complexes  are  poorly 
supported by the electron density (Figure 4). VHELIBS analysis categorized the ligands at 
S1 as  ‘Bad’  in  three  (C1, C2, and C3) out of  the  four structures  (Table 1).  In  the  fourth 
complex  (C4),  the  ligand  (L4)  could  not  be  analyzed  by  VHELIBS.  This  is  because 
VHELIBS  identified L4  to be covalently bonded  to P1, and evaluation of  the quality of 
covalently bound ligands is beyond the scope of VHELIBS. Inspection of the bound pose 
of L4 in P1 revealed that a few ligand atoms are involved in steric clashes with the protein 
binding  site  residues  (Figure S1). The close proximity between  the protein and  ligand 
atoms possibly prompted VHELIBS  to recognize L4 as a covalently bound  ligand. The 
Figure 4. Electron density maps around the ligands bound at site S1 of the structures discussed in case study-1. (A) L1 in
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C1 (2.3 Å). (B) L2 in C2 (2.3 Å). (C) L3 in C3 (2.4 Å). (D) L4 in C4 (2.5 Å). (E) L10 in C17 (2.5 Å). The ligands are shown as
a ball and stick model. The neighboring protein residues are shown as thin sticks. The blue translucent blobs are the ‘2
mFo-DFc’ maps contoured at 1.5σ, surrounding all well-determined atoms in the models. The ‘mFo-DFc’ maps (also called
difference; shown as mesh) are colored as red (negative density difference contoured at -3σ) and green (positive density
difference contoured at +3σ). The red density around an atom indicates either the atom is not present in the crystal or not
well determined by the data or is an indicator of other aspects of incorrect modeling. The green density suggests those
aspects of a structure that are reflected in the experimental data but have not been accounted for in the model. The same
representation styles and contour levels are used in all the figures presented in this article. The images were generated with
the 3D visualizer freely available on the PDBe website. Readers are encouraged to refer to the blog available at the PDBe
website for a detailed explanation and guide [25].
The numerical suffixes to ‘L’ indicate the corresponding complex (C1/C2/C3/C4)
to which the respective ligand is bound at site S1. The ligand L’ at S2 is categorized
as ‘Dubious’ by VHELIBS in all four complexes, indicating no major quality concerns.
Visual inspection confirmed that L’ is adequately supported by the electron density in all
the complexes (Figure 5), but the ligands bound at S1 in all four complexes are poorly
supported by the electron density (Figure 4). VHELIBS analysis categorized the ligands
at S1 as ‘Bad’ in three (C1, C2, and C3) out of the four structures (Table 1). In the fourth
complex (C4), the ligand (L4) could not be analyzed by VHELIBS. This is because VHELIBS
identified L4 to be covalently bonded to P1, and evaluation of the quality of covalently
bound ligands is beyond the scope of VHELIBS. Inspection of the bound pose of L4 in P1
revealed that a few ligand atoms are involved in steric clashes with the protein binding site
residues (Figure S1). The close proximity between the protein and ligand atoms possibly
prompted VHELIBS to recognize L4 as a covalently bound ligand. The reported pose of L4
in C4 not only lacks electron density support but is also energetically unfavored, as evident









Figure 5. Electron density maps around the ligand L’ bound at site S2 of the structures discussed in case study-1. (A) C1.
(B) C2. (C) C3. (D) C4. (E) C17. For details on the resolution of the structures, graphical representation styles, and color
codes of density maps, kindly refer to the legend of Figure 4.
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Table 1. Quality assessment of protein–ligand binding sites in C1–C4, and C17 (case study-1).
Entity
(Ligand/Residue)
VHELIBS * EDIA Analysis PDB Validation Report
Ligand Score; Binding Site
Score; Category EDIAm
a OPIA b Mean B-Factor c Occ. < 1.0 d RSCC e
C1 C2 C3 C4 $ C17 C1 C2 C3 C4 C17 C1 C2 C3 C4 C17 C1 C2 C3 C4 C17 C1 C2 C3 C4 C17 C1 C2 C3 C4 C17
















(41.12) 22 20 0 0 19 0.61 0.23 0.67 0.69 0.78
S1: Phe1 NA 0.56 0.90 0.81 0.69 0.70 27 91 73 36 36 56.53 29.01 35.90 45.28 38.92 0 0 0 0 0 0.93 0.93 0.95 0.94 0.95
S1: Asn55 NA 0.74 0.67 0.70 0.67 0.54 75 50 75 63 38 59.71 41.85 38.72 46.98 53.29 0 0 0 0 0 0.87 0.87 0.86 0.79 0.94
S1: Phe154 NA 0.79 0.77 0.73 0.80 0.68 73 55 55 45 45 57.93 37.09 43.20 45.71 55.62 0 0 0 0 0 0.90 0.93 0.93 0.93 0.94
S1: Glu157 NA 0.36 0.35 0.70 0.55 0.76 44 56 56 44 44 54.83 32.04 36.58 38.39 35.86 3 3 3 3 0 0.96 0.96 0.94 0.93 0.98
S1: Leu158 NA 0.63 0.90 0.76 0.82 0.79 75 75 75 75 75 51.19 29.96 31.86 35.88 29.28 0 0 0 0 0 0.96 0.98 0.98 0.96 0.93
S1: Glu165 NA 0.87 0.84 0.91 0.91 0.84 56 56 78 89 67 57.10 36.72 41.59 47.95 38.21 0 0 0 0 0 0.91 0.95 0.96 0.96 0.92
S1: Arg168 NA 0.38 0.33 0.33 0.26 0.59 45 36 36 36 45 60.94 45.93 45.71 56.23 62.37 6 6 6 6 1 0.96 0.94 0.94 0.92 0.93


















(29.73) 0 0 0 0 0 0.94 0.95 0.98 0.97 0.97
The het codes of the ligands at S1 of C1 (2.3 Å), C2 (2.3 Å), C3 (2.4 Å), C4 (2.5 Å), and C17 (2.5 Å) are L1, L2, L3, L4, and L10, respectively. The het code of the ligands at S2 in all the five structures is L’. The
important residues at site S1 that lack fair electron density support are listed in the table. Kindly note the residue numbers as given in the PDB are not revealed in accordance with our principle of masking
the identities of the structures due to the reason stated in the text. The numbers used here are with reference to the first residue (Phe) in the table which is assigned as residue number ‘1’ in this paper. * A
ligand/binding site is classified as ‘Bad’ (B) by VHELIBS when the score is above 2, indicated in bold. $ As explained in the text, the quality assessment of the ligand (L4) bound at site S1 of C4 could not be
performed with VHELIBS. a An EDIAm score of any fragment (ligand/residue) below 0.8 indicates at least three atoms in that fragment are not well supported by electron density. The values below 0.8 are
shown in bold. b OPIA: overall percentage of well-resolved interconnected atoms; the values below 50 (shown in bold) indicate less than 50% of the interconnected atoms in the particular fragment have good
electron density support. c B-factors are measured in units of Å2. The numbers within the brackets, ‘( )’, in the first and last row indicate the average B-factors of the binding site residues around the respective
ligand. These values were calculated by averaging the mean B-factor of the protein residues (that are within 4.5 Å from the ligand) obtained from the EDIA server. Wherever a ligand’s B-factor is 1.5 times more
than that of its surrounding protein residues, the B-factor of the former is shown in bold, and it demands careful inspection. d Occ. < 1.0: number of atoms in the fragment that have an occupancy less than
unity; cases where one or more atoms have Occ. < 1.0 are shown in bold. Notably, the ligands bound at S1 of C1, C2, and C17 have 22, 20, and 19 non-hydrogen atoms, respectively. None of the atoms in these
ligands have Occ. = 1.0. e RSCC: a score below 0.9 indicates the atoms in the ligand/residue are not well supported by electron density and is shown here in bold. The scores are taken from the respective PDB
validation report.
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EDIA
We subjected the four complexes (C1, C2, C3, and C4) to quality evaluations using
the EDIA server [18] that provides insights into the electron density support for individual
atoms (for details, see Section 4.2). The EDIAm scores for the four ligands (L1, L2, L3, and
L4) bound to S1 of each of the four complexes are 0.40 or below, suggesting poor atomic
density support. The OPIA scores indicate only 15%, 36%, and 14% of the interconnected
ligand atoms in L2, L3, and L4, respectively, are well resolved. L1 has an OPIA score of
0, indicating none of the interconnected atoms in this ligand are well resolved. The EDIA
analysis suggests that L’ bound to site S2 of all the four complexes is of high/medium
quality. These observations correlate well with the VHELIBS assessment report (Table 1).
One of the four ligands (L2) has a two times higher B-factor (64 Å2) than the average
B-factors of the surrounding protein binding site residues (32 Å2), and all the ligand atoms
are modeled with an occupancy of 0.5 (<1.0) (Table 1). Atoms of another ligand, L1, were
also modeled in the respective crystal structure (C1) with an occupancy of 0.5. The B-factor
of L1 (75 Å2) is nearly 1.4 times higher than the average B-factors of binding site residues
(53.4 Å2). The sub-unity occupancies of the atoms in L1 and L2 indicate the presence of
alternate conformations of these ligand atoms. However, the PDB files of the respective
structures report only one set of co-ordinates corresponding to a single conformer of the
mentioned ligands. Considering the resolution (2.3 Å) at which these structures are solved,
the observations on local B-factors and occupancies of the ligand atoms are alarming [23].
In addition, the EDIA analysis indicates that the co-ordinates of some of the critical
protein residues lining binding site S1 need attention (Table 1).
PDB-REDO
The real space correlation coefficient (RSCC) [17] of the four ligands bound to site S1
of C1, C2, C3, and C4 shows no improvement after undergoing re-refinement with the
PDB-REDO pipeline [35]. The ∆RSCC for the mentioned ligands in C1, C2, C3, and C4 are
−0.073, 0.027, −0.029, and 0.105, respectively.
Polder Maps
We assessed the polder (OMIT) maps [22] of all the ligands bound at sites S1 and S2 in
the four structures using the PHENIX suite. The values of correlation coefficients (CC) calcu-
lated between three different types of maps were studied (for details, see Section 4.3). The
densities in the OMIT regions of each of the four polder maps calculated for L’ molecules
are likely to show the ligand atoms. However, the densities in the OMIT regions of the
polder maps calculated for the S1 ligands (L1, L2, L3, and L4) are more likely to indicate
bulk-solvent or noise instead of the ligand atoms. The values of CC(1,3) for the ligands
bound at S1 are 0.74 or below. The CC(1,2) and CC(2,3) for these ligands are 0.65 or below.
These results suggest that the weak densities of the ligands bound at site S1 are not due to
bulk-solvent masking and support the concerns of low confidence of the reported ligand
poses (Table S2).
The consensus results from all the above assessments indicate that the atomic co-
ordinates of the ligands L1, L2, L3, and L4 in the respective PDB entries poorly fit to the
electron density. However, the atomic co-ordinates of the ligand L’ bound to the same
protein structures at a different site (S2) have a good fit to the electron density. Such stark
differences in the quality of local regions (ligand bound to site S1 vs. site S2) within the
same crystal structure were further pronounced in the results of the ligand building test
and docking simulation, as discussed below.
Ligand Building (with ARP/wARP)
The blind fitting attempts (for details, see Section 4.4) for L1 and L2 led to the fitting of
these ligands at site S2 (instead of the expected site S1 as reported in the crystal structures),
with an unusually high normalized bound-state energy. Studies have shown that the nor-
malized bound-state energy of ligands should be within −1.0 and 0.0 kcal·mol−1·atom−1
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(typically −0.37 kcal·mol−1·atom−1) [36]. However, fitting of L1 and L2 at S2 yielded
normalized bound-state energies of ~ 7 kcal mol−1 per atom and ~ 12 kcal mol−1 per atom,
respectively. For L3 and L4, the blind fitting jobs could not be completed successfully,
indicating no suitable site was found for ligand fitting. The guided fitting attempts at site
S1 for L1, L2, L3, and L4 also did not yield energetically favorable ligand poses. However,
the blind fitting attempts for the ligand L’ in all four structures led to fitting the ligand
at site S2 with a highly favorable normalized bound-state energy (~−0.5 kcal mol−1 per
atom). These observations raise concerns on the confidence of the reported co-ordinates of
L1, L2, L3, and L4, thus supporting our earlier results (Table S3).
Docking Simulations
The authors reported in the associated publication that the novel S1 inhibitors were
identified from a virtual screening experiment, and the docked poses of these ligands
(L1, L2, L3, and L4) superimpose well on to their respective bound poses obtained from
crystallographic experiments. This prompted us to perform re-docking simulations of
L1, L2, L3, and L4 at site S1 and L’ at site S2. The top-ranked re-docked poses of the
ligand L’ superimpose well on the reported bound pose of L’ in the respective crystal
structures. However, none of the docked poses of L1, L2, L3, and L4, as predicted in our
study, could reproduce the bound pose of the ligands as seen in the respective crystal
structures (Figure S2).
The authors used the Glide program [37,38] for their docking studies, and we used
the AutoDock vina program [39]. Both these programs are some of the top-performing
docking tools and have been shown to deliver comparable results [40–42]. We appreciate
that docking algorithms have their limitations [43,44] and fail to reproduce bound poses in
many instances. However, the consistent non-reproducibility of the bound poses of the
ligands (L1, L2, L3, and L4) at S1 and the consistent reproducibility of the bound poses of
L’ at S2 for all four structures hint that the co-ordinates of the ligands bound at S1 might
need attention.
Similar analyses, as described for case study-1, were also performed for the subsequent
cases, and a similar trend in the results can be observed. We summarize only the key
findings below.
2.3.2. Case Study-2
This is an example of a crystal structure (C5) of a protein (P2) resolved at an atomic
resolution (1.0 Å) that is bound to two small molecule ligands, where one is the substrate
(L”), and the other is the co-substrate (L5). VHELIBS classified both these ligands and
their corresponding binding sites as ‘Bad’ with a quality score = 4 for each entity. Visual
inspection shows that the ligands are barely supported by electron densities (Figure 6),
which is evident from their EDIA (0.10 and 0.08 for L” and L5, respectively) and OPIA
scores (= 0, for both the ligands). The RSCCs (0.62 and 0.32 for L” and L5, respectively) are
also poor, with no satisfactory improvement upon re-refinement by the PDB-REDO protocol
(Table 2). The densities in the OMIT regions of the polder maps obtained for both the
ligands are more likely to show bulk-solvent or noise instead of the ligand atoms (Table S2).
The literature survey revealed that a mutant of P2 crystallized with a combination of
different substrates (L” and L’”) and co-substrates (L6, L7) is deposited in the PDB as
four separate entries (C6, C7, C8, and C9). All these structures (C6–C9) are resolved at
high resolution (better than 1.8 Å). Visual inspection shows that all the mentioned ligands
and their corresponding protein binding sites in these structures also lack fair support of
electron densities (Figures 6–8). Both the substrates and co-substrates have exceptionally
high B-factors (>1.5 times) compared to the surrounding protein binding site residues in
C5, C6, C7, C8, and C9. The poor fit of the atomic co-ordinates of some of these ligands to
the electron density has also been noted in earlier published reports by other researchers.
Our dataset contains another crystal structure (C10) of P2 bound to L5, which is resolved
at 1.08 Å, reported by a different group of authors. VHELIBS classified L5 in C10 as ‘Good’,
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and visual inspection confirmed that it has an excellent fit to the electron density (Figure 8).
The results of the quality assessment of all the ligands in the six structures (C5–C10) are
presented in Table 2 and Table S2.
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Figure 6. Electron density maps around the ligands (substrate and co-substrate) bound to the
structures (C5 and C6) discussed in case study-2. (A) L” in C5 (1.0 Å). (B) L5 in C5 (1.0 Å). (C) L’”
in C6 (1.1 Å). (D) L6 in C6 (1.1 Å). For details on graphical representation styles and color codes of













Figure 7. Electron density maps around the ligands (substrate and co-substrate) bound to the
structures (C7 and C8) discussed in case study-2. (A) L’” in C7 (1.54 Å). (B) L7 in C7 (1.54 Å). (C) L”
in C8 (1.78 Å). (D) L5 in C8 (1.78 Å). For details on graphical representation styles and color codes of
density maps, kindly refer to the legend of Figure 4.
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The het codes of the substrate ligands (SL) in C5, C6, C7, C8, and C9 are L”, L’”, L’”, L”, and L’”, respectively. The het codes of the co-substrate ligands (CSL) in C5, C6, C7, C8, C9, and C10 are L5, L6, L7, L5, L7,
and L5, respectively. *A ligand/binding site is classified as ‘Bad’ (B) by VHELIBS when the score is above 2, indicated here in bold. a An EDIAm score of any fragment (ligand/residue) below 0.8 indicates at least
three atoms in that fragment are not well supported by electron density. The values below 0.8 are shown in bold. b OPIA: overall percentage of well-resolved interconnected atoms; a value below 50 (shown in
bold) indicates less than 50% of the interconnected atoms in the particular fragment lack good electron density support. Notably, most of the ligands (except the substrate in C8 and co-substrate in C10) have
an OPIA score = 0. c B-factors are measured in units of Å2. The numbers within the brackets, ‘( )’, indicate the average B-factors of the binding site residues around the respective ligand. These values were
calculated by averaging the mean B-factor of the protein residues (that are within 4.5 Å from the ligand) obtained from the EDIA server. Wherever a ligand’s B-factor is 1.5 times more than that of its surrounding
protein residues, the B-factor of the former is shown in bold, and it demands careful inspection. d Occ. < 1.0: number of atoms in the fragment that have an occupancy less than unity. e RSCC: a score below 0.9
indicates the atoms in the ligand/residue are not well supported by electron density and is shown here in bold. The scores are taken from the respective PDB validation report (if available). f ∆RSCC: change in
RSCC after re-refinement. A negative value indicates worse in PDB-REDO. The values in bold indicate insignificant change between final and initial density map fits (quantified by RSCC). Although significant
changes are observed for the ligands in C5, C6, and C9, the density fits are not satisfactory to give a high RSCC. N/A: not applicable.













Figure 8. Electron density maps around the ligands (substrate and co-substrate) bound to the
structures (C9 and C10) discussed in case study-2. (A) L’” in C9 (1.05 Å). (B) L7 in C9 (1.05 Å). (C) L5
in C10 (1.08 Å). For details on graphical representation styles and color codes of density maps, kindly
refer to the legend of Figure 4.
2.3.3. Case Study-3
This is an example of a crystal structure (C11) resolved at a resolution (3.4 Å) poorer
than that of the structures discussed earlier. The authors claim to have captured a unique
transient position of an endogenous ligand (L8) that binds to an enzyme (P3). VHELIBS
classified L8 and its binding site as ‘Bad’. The EDIA scores (EDIAm = 0.23; OPIA = 6) and
visual inspection confirmed that L8 is not supported by the electron density (Figure 2.4). All
the atoms of L8 in C11 have an occupancy below 1. However, the alternate conformation(s)
is (are) not reported. The densities in the OMIT regions of the polder map calculated for
L8 are more likely to show bulk-solvent or noise instead of the ligand atoms. As 3.4 Å
is a comparatively poor resolution, we explored the quality of the identical ligand (L8)
or its analogues (L9) that are bound to protein structures in any PDB entries of similar
resolution. Table 3 lists a few such ligands (L8 and L9) bound to P4, P5, P6, and P7 in the
structures: C12, C13, C14, and C15. These ligands in C12–C15 have a fair electron density
support (Figure 2.4). Another transient position of L8 at the same enzyme’s binding site
(P3) was also reported by the same research group (that reported the structure C11) in the
same year but in a different journal. This structure, C16, is resolved at a better resolution
(2.4 Å) than C11. However, the atomic co-ordinates of L8 in C16 also lack electron density
support (Figure 2.4). The densities in the OMIT region of the polder map calculated for L8
bound to C16 are more likely to show bulk-solvent or noise instead of the ligand atoms
(Table S2). The VHELIBS and EDIA assessment results also agree with these observations
(Table 3 and Table S2). While the re-refined structure of C11 in PDB-REDO shows no
improvement in RSCC of L8, the same for C16 shows a significant (but not considerable)
improvement (Table 3).
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Figure 9. Electron den ity maps around the ligands bound to a few structures discussed in case
study-3. (A) L8 in C11 (3.4 Å). (B) L8 in C13 (3.4 Å). (C) L8 in C14 (3.4 Å). (D) L8 in C16 (2.1 Å). For
details on graphical representation styles and color codes of density maps, kindly refer to the legend
of Figure 4.
2.4. In Silico Assessment of Stereochemical Features of P–L Complexes
We assessed the stereochemical complementarity between selected ligands of interest and
their respective binding sites as per the methodology detailed in Section 4.7. Table S4
summarizes the findings from these analyses. The normalized bound-state energy (Norm.
energy) of two (L8 bound to C16 and C11) out of the three ‘Bad’ rated ligands that were
analyzed is greater than 0, indicating unfavorable interactions. The interface of L8 and its
binding site residues in C16 has several steric clashes. The third ‘Bad’ ligand’s (L1 in C1)
Norm. energy is −0.11 kcal. mol−1 per atom. However, the Norm. electrostatic and Norm.
van der Waals energies are 0. The local packing densities of ligands L1 in C1 and L8 in C16
are 0.49 each. The Norm. energy of the four ‘Good’ rated ligands (L9 in C12 and C15; L8
in C13 and C14) that we analyzed is less than 0. The interfaces of the ‘Good’ ligands and
their binding sites are free of steric clashes. The packing densities of L9 in C12 and C15 are
0.56 and 0.64, respectively. The packing densities of L8 in C13 and C14 are 0.61 and 0.60,
respectively. Few selected structures from case study-2 were subjected to steric clash and
packing density analyses. The ‘Good’ ligand L5 in C10 has a packing density of 0.72, with
no steric clashes. Two out of the other eight ‘Bad’ rated ligands (L5 in C8 and L7 in C7) are
involved in steric clashes with their respective binding site residues. The packing densities
of the other ‘Bad’ ligands, L5 in C5, L” in C5, L’” in C6, L6 in C6, L’” in C7, and L7 in C9, are
0.63, 0.47, 0.52, 0.60, 0.50, and 0.59, respectively. The ligand L4 in C4 could not be analyzed
by VHELIBS, as discussed in Section 2.3.1. Our analysis shows that four atoms of ligand
L4 are involved in ‘Bad’ clashes with two protein (P1) binding site residues (Figure S1).
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3. Discussion
Our results on the assessment of protein–ligand crystal structures show that the
majority (~65%) of the structures have reasonable quality ligand and binding site residues
(Figure 1). Hence, these crystal complexes may (~54% of the structures with quality
categories: GD/DG/DD) or may not (~11% of the structures that are highly reliable:
GG) need any attention before using them as inputs for any structure-based studies. A
total of 35% of structures have either a ‘Bad’ ligand or ‘Bad’ protein binding site, or
both. Notably, the extreme combinations of quality categories, i.e., GB and BG, have
comparatively lower instances (~2% each), implying that it is less likely to observe a ‘Bad’
ligand in a ‘Good’ binding site and vice versa. In other words, the poor quality of one
of the two binding partners (ligand or protein binding site) is likely to affect the other
partner’s quality adversely. For example, the chances of seeing a ‘Good’ electron density
support for a ligand in a highly flexible (manifested as a high B-factor) protein binding
site that gives an ambiguous electron density (‘Bad’) are low. The fit of the model to
density is influenced by the occupancy and B-factor of the atoms. A high B-factor and
low occupancy would decrease scattering contributions, leading to no or poor electron
density. Non-crystallographers are often unaware that atomic co-ordinates supported by
no or weak electron density result from the crystallographer’s subjective interpretations.
Such interpretations are not an outcome of the actual X-ray crystallographic experiments.
The presence of an inadequate electron density to support the existence of a ligand could
also result from bias during protein structure determination. Being unaware of such
nuances may lead to over-interpretation. In the year 2008, Wlodawer et al. [45] reviewed
the technical aspects of crystallography for non-crystallographers. The said article aimed
to educate the users on the parameters that should be evaluated before using the structures,
thereby guiding the users to obtain the best (but not more) from the published atomic co-
ordinates. Our analyses in the current work agree with Wlodawer et al.’s suggestions. The
general analysis presented in this report alerts the user community that ‘high-resolution’
crystal structures deposited in the PDB cannot always be relied upon without verification.
With the help of the specific case studies, we also demonstrated the application of various
freely available tools that aid in the inspection of local structural quality. The consensus
among the results obtained from VHELIBS, the EDIA server, polder maps, and visual
inspection potentiates the fact that the cases highlighted in this article need serious attention.
The additional analyses involving ligand building and docking simulation, as performed
for case study-1 (Section 2.3.1), are also in agreement with the aforementioned results. Our
analyses on the stereochemical features of selected structures are in general agreement
with the quality assessment outcomes from the crystallography data-dependent analyses
(Section 2.4). It is expected that a ‘Good’ ligand is likely to obey the known stereochemical
rules and exhibit favorable interactions with its surrounding environment [13]. Such
expectations are independent of the structure determination techniques. Therefore, local
stereochemical analyses can also be adopted for evaluating the quality of protein–ligand
complexes determined by any experimental technique (crystallography/NMR/cryo-EM)
or predicted by computational methods. Developing a technique-independent pipeline
to assess the local quality of protein–ligand complexes is currently underway in our
group. The findings from the study will be published elsewhere. Our preliminary results
from the current analyses suggest that the ligands rated as ‘Good’ by VHELIBS based
on crystallographic quality indicators have a better stereochemical agreement with the
protein binding sites than the ‘Bad’ ligands. Unlike the ‘Good’ ligands, the ‘Bad’ ligands are
generally less favorably accommodated, less densely packed, and engaged in unjustified
steric clashes.
Through the analyses reported in this article, we aim to contribute to improving the
quality control practices in structural biology research in the ways discussed below.
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3.1. Sensitizing Users
Many users of crystal structures most often rely on the global quality indicator ‘resolu-
tion’ to select input structures from the PDB for virtual screenings or other computational
structure-based studies. As it was discussed earlier (Section 2.2), it is common practice to
discard poorer-resolution structures by defining 2.5 Å as a resolution cut-off. Our analyses
suggest that the ‘Bad’ ligand/protein residues are not restricted to structures of poor reso-
lution (Figure 3). Therefore, users should carefully choose the input structure as its quality
has a crucial impact on the experiment’s outcomes. In general, a high-resolution protein–
ligand crystal structure has lesser uncertainty in the position of atomic co-ordinates than
its low-resolution counterparts. However, the global ‘resolution’ of the structure need not
necessarily guarantee that the reported position and conformation (pose) of ligand/binding
site residues (local regions) agree with the experimental observations. The fit of the model
to the electron density map is a primary indicator of the local model quality and is quanti-
fied by the metric RSCC. Nevertheless, in some instances, the quality is not evident from
the RSCC alone [18] (Table 1).
We acknowledge that visual inspection of electron density maps (Fo-Fc and 2Fo-Fc) for
the local model is the best approach to infer the goodness of fit of the model to experimental
observations. However, visual inspections might not be easily comprehended by novice
users. If the density arising from a local region is weak, then the flat bulk-solvent model
(which is most often used by the present-day crystallographic refinement programs) may
further obscure the density. Decision making for such cases that involve weak densities in
the regions of interest can be challenging. We recommend using multiple freely available
tools that provide a quantitative understanding (such as VHELIBS, EDIA, and polder maps)
to verify the reliability of atomic co-ordinates in the regions of weak densities. Recently,
Yao et al. developed a new metric that can help evaluate structural data with a better
physicochemical context [46]. Users may also consider exploring this new metric that
derives units of electrons directly from electron density maps to indicate the local structural
quality. This tool is available as a Python package (pdb-eda).
If an improved re-refined model of a protein–ligand complex is available in the PDB-
REDO database, it may be preferred over the PDB model for any practical applications [47].
We encourage users to explore the possibilities of optimizing the protein–ligand com-
plexes deposited in the PDB using combined quantum mechanics/molecular mechanics
(QM/M) approaches [48]. Studies have shown that QM/MM optimization of the origi-
nally deposited models in the PDB often improves the ligand and binding site geometry.
Improvement in the ligand geometry may also reduce ligand strain and help improve the
interaction profile between the bound ligand and the binding site residues [49–51]. In many
instances, the co-ordinates of the QM/MM-optimized models are found to have better
agreement with crystallographic quality metrics, such as the standard R, Rfree, and real
space R values. It has also been shown that non-covalent interactions at the protein–ligand
interfaces are generally underestimated in structures determined at a resolution poorer
than 1.5Å [52]. However, the underestimated interactions can be recovered after QM/MM
optimization. Thus, QM/MM optimization of available crystal complexes can provide
better starting points for structure-based drug discovery programs [53].
3.2. Re-Visiting the Structures of Concern by Crystallographers
The authors of the structures with quality concerns might consider re-visiting the
respective projects and providing explanations on the quality of their structures and its
implications. They may also re-visit the PDB entry of their structure and resubmit a better
built model. Attempts to improve the quality of the deposited ‘Bad’ structures either by
re-refinement or re-determination would be a last resort. This can ensure that the broader
user community, which is not trained to analyze the complex crystallographic data, can
focus better on effectively utilizing the data for further research without worrying about
their quality.
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3.3. Proposals to the Journals
An analysis by Brown and Ramaswamy in 2007 [54] indicated that crystal structures of
proteins published in prestigious journals tend to have more errors. One of the reasons the
authors pointed out is the involvement of higher complexities and broader requirements
for accepting an article by the premier journals (“the results should be novel and important for
science as a whole, not solely crystallography”) [54]. We also found that some of the structures
with quality-related concerns at the protein-ligand interfaces, as discussed in this article,
were published in reputed journals. While investigating the first case (as detailed in
Section 2.3.1), we noted a figure of electron density maps around the ligands as provided
by the authors in the associated article. The figure clearly shows that the ligands (L1, L2,
L3, and L4) have no or feeble density support. It could be possible that the said figure
remained unnoticed during the peer review, and eventually the article was published. The
biochemical assays reported in the associated publication show that the ligands L1, L2,
L3, and L4 bind P1 with micromolar affinities (IC50 ranges from ~13 to 50 µM), which are
supposedly not strong binders. The authors designed a series of lead molecules based on
the structure–activity relationship studies of these ligands. One of these molecules (L10)
with better activity (IC50 = 4.2 µM) than the previously reported hits was crystallized with
P1, and results were published in the same journal in the following year. In the L10-P1
complex (C17; 2.5 Å), while L10 is bound at site the S1 of P1, the site S2 is occupied by
L’. The quality assessment details of these ligands are provided in Table 1 and S2. In
agreement with the quality of the earlier structures, the ligand L10 at S1 of C17 has poor
electron density support, but the atomic co-ordinates of L’ at S2 have adequate support
of the experimental electron density (Figures 4 and 5). In-depth probing of the associated
literature revealed that while the authors participated in the molecular modeling, medicinal
chemistry, and biochemical experiments, all the crystallographic experiments reported in
both the publications were performed by an external organization as a part of contract
research. It could be possible that the authors were not intensely involved in analyzing the
crystallographic data and their quality. Given the broad scope of the concerned journal,
the possibility that the manuscripts were reviewed by biologists/chemists who are less
experienced in critically examining crystallographic data cannot be ruled out. To effectively
handle such situations, we propose that the journals and various bodies of the International
Union of Crystallography may consider implementing systems that mandate submissions
of easily interpretable quality reports of local structural data in the form of EDIA and
polder map assessment reports. This can help non-crystallographer stakeholders quickly
access the quality reports for decision making. Towards the goal of having a full-proof
quality check in place, we encourage computational chemists, biologists, and other users
of crystal structures to include analyses of quality scores (EDIA, correlation coefficients
from polder maps for regions of interest with weak density) of the input structures in their
publications. Journals may consider implementing the requirement for inclusion of such
data in computational and related studies. This can prevent the propagation of misleading
results due to possible faulty input structures. We have already embraced the practice of
including discussions on quality assessments of input structures in our publications that
can be referred to in [55–57].
3.4. Proposals to the Repository Community
The structure repository community (PDB) is urged to adopt stringent quality as-
sessment policies, especially for protein–small molecule complexes. Various policies that
include archiving the raw data and implementation of correctional measures upon detect-
ing an error have already been suggested by many experts [58,59]. Initiatives to establish
an independent international committee to periodically monitor the quality of the PDB
structures have also been taken [60,61]. Additionally, from a non-crystallographer’s per-
spective, we propose that the PDB validation report should integrate metrics that provide
users with a better understanding of the local quality by quantifying how well each atom
(especially for the ligands of interest and their binding sites) is supported by the electron
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density. The RSCC, as available from the PDB validation reports, serves as a local quality
indicator. However, unlike EDIA scores, it does not provide atomic-level understandings.
As discussed earlier, verifying the existence of atoms in regions of weak densities is chal-
lenging if the densities are masked by a bulk-solvent density. Under such circumstances,
polder map assessment can aid decision making. Therefore, integrating EDIA and polder
map assessment into the existing PDB validation pipeline could be helpful to users. For
the already deposited structures, EDIA and polder map assessment on ligands and protein
binding site residues should be performed. The results from these assessments should be
made publicly available to educate the users on the quality of the deposited structures.
Explanations from the authors should be mandated where the parameters deviate from
the standard criteria. Policies should be in place to correct any detected error within a
stipulated time period with documentation of the reasons for removal of faulty structures.
We believe the suggested efforts can complement the existing quality control measures and
help maintaining the integrity of the structural repositories. In the words of Minor et al.,
these measures can help in “safeguarding structural data repositories against bad apples” [59].
4. Materials and Methods
We assessed the quality of protein–small molecule crystal complexes deposited in the
Protein Data Bank (PDB) [4] against the available crystallography-dependent parameters.
Selected cases were subjected to detailed studies. The tools and/or resources and the
methodology adopted for the analysis are elaborated below.
4.1. Dataset
All small molecule (70 Da ≤ molecular weight ≤ 800 Da) bound protein structures
were downloaded from the PDB in July 2019. Only those structures where the small
molecule contains at least one carbon atom were considered for further analysis. This initial
dataset comprised ~92,000 unique PDB entries.
4.2. Quality Assessment of Protein–Ligand Binding Sites
Henceforth, only the structures determined using X-ray crystallography were con-
sidered for quality assessment. The quality of the protein–ligand binding sites in all the
crystal complexes was assessed using the tool Validation HElper for LIgands and Binding
Sites (VHELIBS) [21]. Given a protein–ligand (non-covalently bound) crystal complex,
this tool categorizes the binding site of the input structure in either of the following
nine possible classes: (i) Good/Good (GG), (ii) Good/Dubious (GD), (iii) Good/Bad (GB),
(iv) Dubious/Good (DG), (v) Dubious/Dubious (DD), (vi) Dubious/Bad (DB), (vii) Bad/Good
(BG), (viii) Bad/Dubious (BD), and (ix) Bad/Bad (BB). The first quality label indicates the
bound ligand’s quality, and the second label indicates the quality of the protein binding
site. Hence, if a protein–ligand binding site is labeled as ‘Good/Good’ or ‘GG’, it indicates
that the ligand and all the protein binding site residues have a quality score = 0, suggesting
highly reliable atomic co-ordinates. For VHELIBS assessment, we defined the binding
site as a region that consists of residues within 4.5Å of the bound ligand. We preferred
to use the abbreviated forms of the quality labels, denoting each category with its first
letter for the ease of our discussion. VHELIBS assessed the bound ligand and each protein
binding site residue of the input structures against the parameters mentioned below and
their corresponding specified limits:
(a) Maximum Real Space R-factor (RSR): 0.4;
(b) Maximum ‘Good’ RSR: 0.24;
(c) Minimum ‘Good’ real space correlation coefficient (RSCC): 0.9;
(d) Average occupancy: 1.0;
(e) Occupancy weighted average B-factor (OWAB): 50 Å2;
(f) Maximum Rfree: 0.3;
(g) Maximum [(Rfree) − (Rwork)] value: 0.05.
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Deviation from the specified limits for any of the above parameters would lead to
a penalty with an increment in the quality score of ‘1’. Therefore, if there is no devi-
ation from the specified limits of all the mentioned parameters, the score assigned to
the ligand/binding site residue is 0. The entity (ligand/binding site residue) is then
categorized as ‘Good’ (G). If there are deviations with respect to, at most, any two pa-
rameters (0 < score ≤ 2), then the entity is labeled as ‘Dubious’ (D). A ligand/protein
residue that is labeled as ‘Dubious’ may or may not be of severe concern. Such a structure
may be re-classified by the user as ‘Good’ or ‘Bad’ after visual inspection, depending
upon the criticality of the question that the user aims to address using the input structure.
A score > 2 categorizes the particular entity as ‘Bad’ (B) and serious attention before using
the structure for any practical applications might be needed. A higher score indicates a
poorer quality of the ligand/residue. The protein binding site is assigned a quality label
based on the highest score that any residue receives among all the residues within the
bound ligand’s specified radius. Thus, even if a single residue in a protein binding site
receives a score >2, the binding site will be labeled as ‘Bad’ by VHELIBS. The program lists
such residues for examination. Hence, it is advisable that the user should visually examine
the ligand and residues while performing analysis with a small dataset to decide on further
applicability of the structure. The default ligand ‘exclusion’ list of VHELIBS was modified
so that all ligands (except water or similar solvents and metal ions), irrespective of their
biological relevance, are considered for the analyses. The crystal structures deposited in
the PDB without the information on respective structure factor files could not be assessed.
A total of 66,851 unique PDB entries corresponding to ~0.28 million (276,377) pairs of
non-covalently bound small molecule ligands and protein binding site residues could be
evaluated.
For selected cases, detailed quality assessments were performed using the EDIA
tool [18] available at the ProteinsPlus webserver (https://proteins.plus/; we last accessed
this website on 19 May 2021) [62]. The electron density score for individual atoms (EDIA)
quantifies the electron density fit of an atom. The EDIA tool combines the atomic EDIA
values with the help of the power mean to compute EDIAm, the electron density score for
any entity (small molecules, fragments, or residues). EDIA score≥ 0.8 indicates satisfactory
electron density support for the entity. A score of 0.4 ≤ EDIA score < 0.8 suggests medium
electron density support for the atoms, and a score below 0.4 means poorly supported
atoms. An EDIAm below 0.8 indicates at least three atoms in the ligand/residue under
consideration have an EDIA below 0.8. Additionally, the tool provides another score
called OPIA, overall percentage of well-resolved interconnected atoms. This score allows
distinguishing between overall poorly supported ligands and ligands with partially unsup-
ported substructures. The PDB-REDO database containing re-refined structures of many
existing PDB entries was also consulted for selected example cases to check improvements
in RSCC [35].
4.3. Polder Map Assessment
The tool polder.phenix implemented in the PHENIX software suite was used to generate
polder (OMIT) maps to test the quality of ligands [22]. An OMIT map is computed by
excluding the selected atoms from the structure and updating the corresponding structure
factors, followed by calculating a map. It is expected that the electron density for the
omitted (excluded) atoms will be seen as positive features in the OMIT map if the atoms
are actually present in the crystal structure. Polder (OMIT) maps do not apply bulk-solvent
flattening around the selected OMIT regions (which are the ligand atoms in our study)
to better assess the presence of ligands (the electron density of which might be obscured
sometimes due to bulk-solvent flattening). The polder approach computes three maps: m1,
m2, and m3. Maps m1 and m2 are calculated using synthetic data (Fobs = |Fmodel|), one
assuming that the omitted atoms are present (m1) and the other assuming that the omitted
atoms are absent (m2). Map m3 is the polder map that uses actual experimental data. Local
correlation coefficients (CC) between all pairs of the three maps are then computed. By
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design of the test, m1 is expected to show omitted atoms, and m2 is expected to show a
bulk-solvent density. If the polder map (m3) shows the omitted atoms, it is expected to best
correlate with m1. On the contrary, if m3 shows bulk-solvent, it is expected to correlate best
with map m2. However, if the omitted atoms are highly mobile (as indicated, for example,
by high B-factors) and/or the resolution of the structure is low, m1 may instead be smeared.
It could then resemble the bulk-solvent map, generating a high correlation with map m2.
Therefore, a sufficiently higher CC between m1 and m3 than the other two pairs of CC
(m1–m2 and m2–m3) suggests that the polder map is likely to show the omitted atoms.
The inputs for generating a polder map for selected omit regions include two files: the
model (.pdb) and reflection data files (.mtz) as available from the PDB.
4.4. Ligand Building
The ARP/wARP program webservice was accessed through https://arpwarp.embl-
hamburg.de/ (we last accessed this website on 19 May 2021) to build the ligands in the
density maps of the selected structures [36] by using: (a) respective phase information and
(b) the atomic co-ordinates of the protein, available in the PDB. The ligand fitting trials
were performed in the following ways: (a) blind fitting, and (b) guided fitting. For the blind
fitting, the program was instructed to place the ligand at the best site of the input protein
structures. For the guided fitting, co-ordinates of approximately the central atom of the
ligands (as available from their corresponding PDB files) were chosen, and the ARP/wARP
program was instructed to search for a suitable ligand position within a 3 Å radius of
the specified set of co-ordinates. The program also reports normalized energy for the
ligands fitted in the respective protein binding site, which serves as a validation parameter
to indicate the fit’s goodness in terms of favorable interactions with the protein binding
site. Normalized bound-state energy should be within −1.0 and 0.0 kcal.mol−1.atom−1
(typically −0.37 kcal.mol−1.atom−1) [36]. A value above 0.0 kcal.mol−1 per atom indicates
a likely case of ligand misfit, which is not energetically favored by the protein binding site.
4.5. Docking Simulation
Guided docking simulations within pre-defined grid boxes (that were centered around
the ligands of interest) were performed for case study-1 using AutoDock vina [39] to
generate 20 binding poses per ligand with an energy range of 9 kcal mol−1.
4.6. Visualization and Graph Plotting
The academic version of PyMol (Schrödinger, LLC) was used for visualizing the
molecules. The Mol* 3D viewer on the PDBe website was used to visualize the electron
density maps around the ligands and generate the images [24,25]. Microsoft Excel and
Python seaborn libraries [63] were used for plotting the graphs. In Figure 2, the year-
wise percentage of protein–ligand (P–L) binding site pairs in each category is calculated
as below.
%P− L binding site pairs = Number of P− L binding site pairs in the particular category in a given year× 100
Total number of P− L binding site pairs in the dataset (1)
4.7. In Silico Approach to Assess Stereochemical Quality of P–L Binding Sites
For selected cases, the quality of P–L binding sites was assessed against the following
stereochemical features: (i) steric clashes, (ii) energy, and (iii) ligand packing density. The
P–L pairs with missing residues/atoms (within 6 Å of the bound ligand) in the electron
density maps of the respective binding sites could not be considered for the analyses.
Only the cases with extreme ligand quality ratings (‘Good’ and ‘Bad’) as assigned by
VHELIBS were included in the analyses. The calculations of the mentioned stereochemical
parameters are based on the reported 3D co-ordinates of the ligand/residues. Therefore,
the results are influenced by the inherent co-ordinate errors of the structures. Generally, the
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poorer the resolution of the structure, the larger the co-ordinate errors. Hence, the values
of different parameters reported here for each structure are limited by their resolution.
The steric clashes at the interfaces of the proteins and small molecules of interest were
analyzed using the CLASHSCORE module [64] in the PHENIX software suite. This module
calculates all-atom contacts and classifies an overlap of greater than or equal to 0.4 Å as
a ‘Bad clash’. Only the non-hydrogen atoms of the ligand and the protein binding site
residues that are not engaged in hydrogen bonding are considered for reporting in our
steric clash analyses.
The bound-state energy of the ligand pose reported in the respective PDB files was calcu-
lated using the AutoDock scoring function implemented in the compute_AutoDock41_score.py
script available in the MGLTools package. The input ‘pdbqt’ files of the proteins and the
ligands required for the energy calculations were prepared using the prepare_receptor4.py
and prepare_ligand4.py scripts from the MGLTools package available for proteins and
small molecules, respectively [65]. The Autodock4 scoring function is based on a semi-
empirical energy force field. The overall energy score comprises the following components:
electrostatics, hydrogen bonding, van der Waals, torsion, and desolvation [66]. The energy
scores of each P–L pair were normalized against the total number of non-hydrogen atoms
in the respective ligands to avoid the influence of the ligand size on energy calculations.
An energy score above 0 indicates an unfavorable interaction between the protein and
the ligand. A more negative score indicates better stereochemical complementarity be-
tween the two binding partners. The energy calculations in this study did not consider
any water/ion/other ligand-mediated interactions between the protein binding site and
ligand of interest. Therefore, we did not perform energy calculations on the structures
that contain more than one ligand of interest in the protein binding sites to avoid possible
under-estimation of energy scores. These are the structures discussed in case-study 2,
where the enzyme active sites are occupied by two ligands—a substrate and a cofactor,
each influencing the interaction profile of the other.
The local packing densities of the ligand atoms were calculated using the Voronoia
program [67]. The packing density of atoms involved in steric clashes are unreliable and
are therefore not considered for reporting. The packing density values range from 0 to 1.
The higher the value, the denser the atomic packing.
4.8. Software Details
The following versions of the different software were used in this study.
(a) VHELIBS version 4.3 [68]
(b) Autodock Vina version 1.1.2 [69]
(c) Polder map module available in Phenix 1.19.2-4158 [70,71]
(d) Clashscore module available in Phenix 1.19.2-4158 [70,71]
(e) PyMol version 2.4.0 [72]
(f) Voronoia version 1.0 [73]
(g) MGL Tools version 1.5.6 [74]
5. Conclusions
The structural co-ordinates submitted in the PDB serve as the important starting
points of many interdisciplinary research projects in both academia and industries. In
particular, the drug discovery programs are heavily dependent on the availability of high-
quality structural data of protein–ligand complexes. Our analyses of ~0.28 million binding
sites derived from crystal structures corresponding to ~66,000 PDB entries revealed that
only 11% of the small molecule and protein binding site pairs are highly reliable. In
contrast, the remaining 89% pairs might need little or serious attention before usage.
Previously, many expert crystallographers have suggested users to verify the quality of
the structural data by inspecting the experimental data. However, most users of crystal
structures are non-crystallographers who are not trained to comprehend the complex
crystallographic data. Hence, such analyses can be time-consuming and challenging to
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perform, especially for large-scale data investigations in bioinformatics-centric studies. To
tackle this problem, we encourage users to explore the application of more straightforward
tools that quantify the goodness of fit of individual atoms (EDIA) and, in case of weak
densities, verify the presence of the atoms of interest by masking the bulk-solvent density
(polder maps). Through the various case studies discussed in this article, we sensitize
the user community about the old saying ‘all that glitters is not gold’. The first case study
(Section 2.3.1) demonstrates how the confidence on the atomic co-ordinates of two ligands
bound to different sites within the same protein can starkly vary even when the structures
are resolved at a modest resolution (~2.5 Å or better). The second case study highlights
structures with near-atomic resolution (Section 2.3.2), but the confidence associated with the
reported ligand co-ordinates is low. The third case study (Section 2.3.3) shows an example
of a crystal structure with a comparatively lower resolution (3.4 Å) and a poor support of the
atomic co-ordinates by electron density. Our analyses show that co-ordinates of many other
similar ligands (identical/chemical analogues) crystallized with other proteins and resolved
at the same resolution (3.4 Å) have moderately better agreement with their corresponding
electron density maps. Therefore, the users must be vigilant about the local regions’ quality,
irrespective of the resolution at which the crystal structure is determined. Further, our
preliminary findings on exploring stereochemical features as local quality indicators of
protein–ligand complexes agree with the evaluation reports based on crystallography-
dependent data.
Having sensitized the users about the prevailing problems, we also proposed a few so-
lutions for the scientific community at large to consider for discussion and implementation.
We note that some of our proposals resonate with the initiatives and recommendations
discussed by Minor et al. [59]. Archiving raw experimental data in publicly available repos-
itories would immensely help verify the quality of the local regions in a model. However,
the usage of such data is likely to be restricted to only expert users with sound knowledge
of crystallography. Hence, we believe complementing the data archival initiatives by
integrating metrics that express local models’ quality in a quantifiable manner would help
non-crystallographers quickly verify the structural data quality. In the years to come, these
initiatives would boost quality research practices in the broad area of structural biology.
Finally, we would like to state that ‘absence of evidence is not evidence of absence’. Hence, the
lack of electron density support for a region of interest does not necessarily mean that
the respective atoms were absent during the experiment. There can be several reasons,
as discussed earlier, that can lead to no or poorly interpretable electron density. Users
should be careful about such structures and must apply their general physical chemistry
understandings to judge if a local region that does not pass the quality checks could be
used as an input for their research to obtain meaningful biological insights.
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